Wide Ranks

ABCL

AbCellera Biologics Inc.

3.00

Top Statistics
Market Cap 886 M Forward PE -4.44 Revenue Growth -1.40 %
Current Ratio 9.34 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -1.41 Enterprise / Revenue 9.54 Price To Sales Trailing12 Months 26.88
Profitability
Profit Margins 0.00 % Operating Margins -1439.42 %
Balance Sheet
Total Cash 643 M Total Cash Per Share 2.18 Total Debt 71 M
Total Debt To Equity 6.62 Current Ratio 9.34 Book Value Per Share 3.65
All Measures
Short Ratio 639.00 % Message Board Id finmb_280568380 Shares Short Prior Month 17 M
Return On Equity -0.1555 City Vancouver Uuid 3bee7a8c-17d1-3746-82e5-1968755076f0
Previous Close 2.83 First Trade Date Epoch Utc 1 B Book Value 3.65
Beta 0.3510 Total Debt 71 M Volume 4 M
Price To Book 0.8212 Fifty Two Week Low 2.33 Total Cash Per Share 2.18
Total Revenue 32 M Shares Short Previous Month Date 1 B Target Median Price 9.00
Audit Risk 8 Max Age 86400 Sand P52 Week Change 0.3133
Operating Margins -1439.42 % Target Mean Price 12.29 Net Income To Common -175796992
Short Percent Of Float 0.0700 Implied Shares Outstanding 295 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 2 M Average Volume10days 2 M
Total Cash 643 M Next Fiscal Year End 1 B Revenue Per Share 0.1120
Held Percent Insiders 0.2802 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Share Holder Rights Risk 4 Regular Market Previous Close 2.83
Target Low Price 5.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 2.70
Open 2.88 Free Cashflow -105576000 State BC
Dividend Yield 0.00 % Return On Assets -0.1326 Time Zone Short Name EST
Board Risk 9 Trailing Eps -0.6100 Day Low 2.87
Address1 2215 Yukon Street Shares Outstanding 295 M Compensation Risk 8
Price Hint 4 Target High Price 28.00 Website https://www.abcellera.com
52 Week Change -0.3631 Average Volume 2 M Forward Eps -0.6600
Recommendation Key none Compensation As Of Epoch Date 1 B Quick Ratio 887.80 %
Is_sp_500 False Regular Market Day High 3.07 Profit Margins 0.00 %
Debt To Equity 6.62 Fifty Two Week High 6.05 Day High 3.07
Shares Short 15 M Regular Market Open 2.88 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 9.54 Revenue Growth -1.40 %
Shares Percent Shares Out 0.0539 Operating Cashflow -120167000 Currency USD
Time Zone Full Name America/New_York Market Cap 886 M Is_nasdaq_100 False
Zip V5Y 0A1 Quote Type EQUITY Industry Biotechnology
Long Name AbCellera Biologics Inc. Overall Risk 8 Regular Market Day Low 2.87
Held Percent Institutions 0.3824 Current Price 3.00 Enterprise To Ebitda -1.41
Financial Currency USD Current Ratio 9.34 Industry Disp Biotechnology
Number Of Analyst Opinions 7 Country Canada Float Shares 189 M
Two Hundred Day Average 3.40 Governance Epoch Date 1 B Enterprise Value 314 M
Price To Sales Trailing12 Months 26.88 Forward PE -4.44 Regular Market Volume 4 M
Ebitda -222243008 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development.

Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies.

The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.

It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners.

The company was incorporated in 2012 and is headquartered in Vancouver, Canada.